Saw where you posted the following on the Stockman forum. It looked like we SI folk should share it:
The Feb 3 release is one of the most important in the public history of MTEN. Here's why:
1) While the $50,000 initial grant may seem like a small number, this is federal money, folks! Funding for the next stages of this critical study could well run into substantial dollars.
2) What this symbolizes is the groundswell of recognition that detectable, correctable eye conditions in the very young should be dealt with as quickly and inexpensively as possible. Amblyopia, or lazy eye, is a condition OWNED by MTEN.
3) The important new strategic direction is towards driving local, state and federal health authorities to MANDATE early photoscreening for kids. Since MTEN's patented MTI PhotoScreener (tm) is really the only game in town, very cost effective and does not require dilating a squirming child's eyes, any such mandate must benefit MTEN to an unimaginable degree. It's like the Feds mandating tomato soup for breakfast in every school program -- there's only only one company that can benefit, right?
4) MTEN has already disclosed that its marketing partner, Polaroid, has budgeted $250,000 to hire a Washington lobbying firm to begin a campaign to mandate photoscreening as mentioned above. Mind you, Polaroid is paying for this, not MTEN. We could see results from this campaign in the next twelve months -- after all, this is a popular cause which pays for itself in avoidance of expensive corrective operations later in a child's life.
5) Today, Feb. 3, the new President of MTEN, Bob Brennan, takes office and begins duties as Chief Operating Officer. Chairman Jeremy Feakins can now devote almost all his time to working with the lobbyists and making key sales. It's a great step forward for the company.
6) Feakins is addressing roadshows this week to explain the shift in
corporate strategy from retail (doctor-by-doctor) to wholesale (Bergen
Brunswig, optical chains like Lens Crafters, mandated government programs, etc.). Schedule: Philadelphia today, Washington Feb. 4, Boston Feb. 5.
Bottom line: MTEN is making real progress as a public company. Its stock price will eventually catch up to its improving performance and its unique position in public health and private medical practice.
Warren Cavior
(IR counsel to MTEN) |
